Context: Bone health declines in the initial years after Roux-en-Y gastric bypass (RYGB), but long-term skeletal effects are unclear. Objective: To document longitudinal changes in bone mineral density (BMD) and microarchitecture 5 years after RYGB. Design, Setting, and Participants: Prospective 5-year observational study of 21 adults with severe obesity receiving RYGB at an academic medical center. Main Outcome Measures: Spine and hip areal BMD were measured by dual-energy X-ray absorptiometry, and trabecular volumetric BMD (vBMD) of the spine was assessed by quantitative CT (QCT). We measured vBMD and microarchitecture of the distal radius and tibia by high-resolution peripheral QCT in a subset of subjects. Serum type I collagen C-terminal telopeptide (CTX) and procollagen type I N-terminal propeptide (P1NP) were also measured. Results: Areal BMD declined by -7.8% ± 7.6% at the spine and -15.3% ± 6.3% at the total hip by 5 years after RYGB (P ≤ 0.001), although the rate of bone loss slowed in later years. Trabecular spine vBMD decreased by -12.1% ± 12.3% by 5 years (P ≤ 0.001). At peripheral sites, vBMD continued to decrease steadily throughout 5 years, with parallel declines in cortical and trabecular microarchitecture, leading to decreases in estimated failure load of -20% and -13% at the radius and tibia, respectively (P < 0.001). Five years after RYGB, CTX and P1NP were 150% and 34% above baseline (P < 0.001 and P = 0.017, respectively). Conclusions: Sustained high-turnover bone loss and bone microarchitectural deterioration occur in the 5 years after RYGB. Adults receiving RYGB warrant assessment of bone health.
Context: Bone health declines in the initial years after Roux-en-Y gastric bypass (RYGB), but long-term skeletal effects are unclear. Objective: To document longitudinal changes in bone mineral density (BMD) and microarchitecture 5 years after RYGB. Design, Setting, and Participants: Prospective 5-year observational study of 21 adults with severe obesity receiving RYGB at an academic medical center. Main Outcome Measures: Spine and hip areal BMD were measured by dual-energy X-ray absorptiometry, and trabecular volumetric BMD (vBMD) of the spine was assessed by quantitative CT (QCT). We measured vBMD and microarchitecture of the distal radius and tibia by high-resolution peripheral QCT in a subset of subjects. Serum type I collagen C-terminal telopeptide (CTX) and procollagen type I N-terminal propeptide (P1NP) were also measured. Results: Areal BMD declined by -7.8% ± 7.6% at the spine and -15.3% ± 6.3% at the total hip by 5 years after RYGB (P ≤ 0.001), although the rate of bone loss slowed in later years. Trabecular spine vBMD decreased by -12.1% ± 12.3% by 5 years (P ≤ 0.001). At peripheral sites, vBMD continued to decrease steadily throughout 5 years, with parallel declines in cortical and trabecular microarchitecture, leading to decreases in estimated failure load of -20% and -13% at the radius and tibia, respectively (P < 0.001). Five years after RYGB, CTX and P1NP were 150% and 34% above baseline (P < 0.001 and P = 0.017, respectively). Conclusions: Sustained high-turnover bone loss and bone microarchitectural deterioration occur in the 5 years after RYGB. Adults receiving RYGB warrant assessment of bone health.
Authors: David E Arterburn; Maren K Olsen; Valerie A Smith; Edward H Livingston; Lynn Van Scoyoc; William S Yancy; George Eid; Hollis Weidenbacher; Matthew L Maciejewski Journal: JAMA Date: 2015-01-06 Impact factor: 56.272
Authors: A M Kriska; W C Knowler; R E LaPorte; A L Drash; R R Wing; S N Blair; P H Bennett; L H Kuller Journal: Diabetes Care Date: 1990-04 Impact factor: 19.112
Authors: Megan R Crawford; Nathan Pham; Leila Khan; James F Bena; Philip R Schauer; Sangeeta R Kashyap Journal: Endocr Pract Date: 2017-11-16 Impact factor: 3.443
Authors: Torsten Olbers; Sofia Björkman; Ak Lindroos; Almantas Maleckas; Lars Lönn; Lars Sjöström; Hans Lönroth Journal: Ann Surg Date: 2006-11 Impact factor: 12.969
Authors: Xavier Nogués; Albert Goday; Maria Jesus Peña; David Benaiges; Marta de Ramón; Xenia Crous; Manuel Vial; Manuel Pera; Luis Grande; Adolfo Díez-Pérez; Jose Manuel Ramón Journal: Cir Esp Date: 2010-07-08 Impact factor: 1.653
Authors: Jason M Johnson; James W Maher; Isaac Samuel; Deborah Heitshusen; Cornelius Doherty; Robert W Downs Journal: J Gastrointest Surg Date: 2005-11 Impact factor: 3.452
Authors: Penelope S Coates; John D Fernstrom; Madelyn H Fernstrom; Philip R Schauer; Susan L Greenspan Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Arief Lalmohamed; Frank de Vries; Marloes T Bazelier; Alun Cooper; Tjeerd-Pieter van Staa; Cyrus Cooper; Nicholas C Harvey Journal: BMJ Date: 2012-08-03
Authors: C Gronnier; F Tremollieres; Blandine Gatta-Cherifi; O Cadart; O Degrandi; T Barnetche; N Mehsen-Cetre; M Monsaingeon-Henry; E Pupier; L Bosc; D Collet Journal: Obes Surg Date: 2020-09 Impact factor: 4.129
Authors: Madhusmita Misra; Vibha Singhal; Brian Carmine; Amita Bose; Megan M Kelsey; Fatima Cody Stanford; Jennifer Bram; Jeremy Aidlen; Thomas Inge; Mary L Bouxsein; Miriam A Bredella Journal: Bone Date: 2020-02-19 Impact factor: 4.398
Authors: Elaine W Yu; Seoyoung C Kim; Daniel J Sturgeon; Katherine G Lindeman; Joel S Weissman Journal: JAMA Surg Date: 2019-08-01 Impact factor: 14.766
Authors: Paul A Baldock; Jacqueline R Center; Malgorzata M Brzozowska; Thach Tran; Dana Bliuc; John Jorgensen; Michael Talbot; Douglas Fenton-Lee; Weiwen Chen; Angel Hong; Alex Viardot; Chris P White; Tuan V Nguyen; Nicholas Pocock; John A Eisman Journal: Int J Obes (Lond) Date: 2020-08-26 Impact factor: 5.095